| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -8,893 | -5,216 |
| Sale of investments | - | 0 |
| Net cash provided by investing activities | - | 0 |
| Exercise of warrants and issuance of inducement warrants for cash, net | 1,052 | 1,052 |
| Proceeds from issuance of series l convertible preferred stock and warrants, net | 6,503 | 5,441 |
| Payment of dividend on series l convertible preferred stock | 85 | - |
| Net cash provided by financing activities | 7,470 | 6,493 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -1,423 | 1,277 |
| Cash and cash equivalents at beginning of period | 4,044 | - |
| Cash and cash equivalents at end of period | 2,621 | - |
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)